XML 62 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Restatement of Previously Issued Financial Statements (Tables)
 3 Months Ended
Mar. 31, 2021
CM Life Sciences, Inc.  
Restatement Of Previously Issued Financial Statements [Line Items]  
Schedule of previously reported operating expenses, cash flows or cash
The Company’s accounting for the warrants as components of equity instead of as derivative liabilities did not have any effect on the Company’s previously reported operating expenses, cash flows or cash.
As
Previously
Reported		AdjustmentsAs
Restated
Balance sheet as of September 4, 2020 (audited)
Warrant Liabilities$— $43,462,868 $43,462,868 
Class A Common Stock Subject to Possible Redemption423,731,850 (43,462,868)380,268,982 
Class A Common Stock190 434 624 
Additional Paid-in Capital5,001,390 12,855,371 17,856,761 
Accumulated Deficit(2,681)(12,855,805)(12,858,486)
Total  Stockholders’ Equity5,000,006 — 5,000,006 
Balance sheet as of September 30, 2020 (unaudited)
Warrant Liabilities$— $48,148,484 $48,148.484 
Class A Common Stock Subject to Possible Redemption423,677,610 (48,148,484)375,529,126 
Class A Common Stock191 481 672 
Additional Paid-in Capital5,055,629 17,540,941 22,596,570 
Accumulated Deficit(56,923)(17,541,422)(17,598,345)
Total Stockholders’ Equity5,000,004 — 5,000,004 
Balance sheet as of December 31, 2020 (audited)
Warrant Liabilities$— $70,322,418 $70,322,418 
Class A Common Stock Subject to Possible Redemption423,542,290 (70,322,420)353,219,870 
Class A Common Stock192 703 895 
Additional Paid-in Capital5,190,948 39,714,654 44,905,602 
Accumulated Deficit(192,244)(39,715,355)(39,907,599)
Total Stockholders’ Equity5,000,003 2 5,000,005 
Period from July 10, 2020 (inception) to September 30, 2020 (unaudited
Change in value of warrant liability$— $16,336,651 $16,336,651 
Transaction costs— 1,204,771 1,204,771 
Net loss(56,923)(17,541,422)(17,598,345)
Weighted average shares outstanding of Class A redeemable common stock
44,275,000 — 44,275,000 
Basic and diluted earnings per share, Class A redeemable common stock
— — — 
Weighted average shares outstanding of Class B non-redeemable common stock
11,068,750 — 11,068,750 
Basic and diluted net loss per share, Class B non-redeemable common stock
(0.01)(1.58)(1.59)
Period from July 10, 2020 (inception) to September 30, 2020 (Unaudited)
Change in value of warrant liability$— $38,510,584 $38,510,584 
Transaction costs— 1,204,771 1,204,771 
Net loss(192,244)(39,715,354)(39,907,599)
Weighted average shares outstanding of Class A redeemable common stock
44,275,000 — 44,275,000 
Basic and diluted earnings per share, Class A redeemable common stock
— — — 
Weighted average shares outstanding of Class B non-redeemable common stock
10,633,062 — 10,633,062 
Basic and diluted net loss per share, Class B non-redeemable common stock
(0.02)(3.73)(3.75)
Cash Flow Statement for the Period from July 10, 2020 (inception) to September 30, 2020 (unaudited)
Net loss$(56,923)$(17,541,422)$(17,598,345)
Allocation of initial public offering costs to warrant liability— 1,204,771 1,204,771 
Change in fair value of warrant liability— 16,336,651 16,336,651 
Initial classification of warrant liability— 31,811,834 31,811,834 
Initial classification of common stock subject to possible redemption423,731,850 (43,462,868)380,268,982 
Change in value of common stock subject to possible redemption(54,240)(4,685,617)(4,739,857)
Cash Flow Statement for the Period from December 31, 2020 (inception) to December 31, 2020 (audited)
Net loss$(192,244)$(39,715,355)$(39,907,599)
Change in fair value of warrant liability— 38,510,584 38,510,584 
Allocation of initial public offering costs to warrant liability— 1,204,771 1,204,771 
Initial classification of warrant liability— 31,811,834 31,811,834 
Initial classification of common stock subject to possible redemption423,731,850 (43,462,868)380,268,982 
Change in value of common stock subject to possible redemption(1,539,252)(25,509,860)(27,049,112)